Stock listing

gettex:RXK3 SELLAS Life Sciences Group, Inc. Aktie

German listing (gettex) of SELLAS Life Sciences Group, Inc. · home listing NASDAQ:SLS

Follow SELLAS Life Sciences Group, Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:SLS

$9.98 USD -1.36 (-12.0%)

Close on Oct 16, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:SLS

Since Jul 6, 2026 -28.4% · daily closes, Jul 6, 2026 – Oct 16, 2026, adjusted for splits
Day range
$9.75 – $11.24 USDOct 16, 2026
Volume
15.77M sharesOct 16, 2026
Market value
$2.02B USDAt the close on Oct 16, 2026 · price × 201.9M shares outstanding
SELLAS Life Sciences Group, Inc. logo
Ticker
gettex:RXK3
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
gettex
Currency
EUR

What changed lately

Calls

Replays

  • SELLAS Life Sciences Group (NASDAQ:SLS) Q2 2022 Earnings Call

    Thu, Sep 15, 2022 · 1:00 PM ET

    Watch Transcript

Latest news

SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer

Sep 25, 2026

SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer

Sep 2, 2026

SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 12, 2026

SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update

Mar 19, 2026

SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference

Mar 17, 2026

SELLAS Life Sciences Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

Mar 12, 2026

SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe

Jan 14, 2026

SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

Dec 29, 2025

SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025

Dec 7, 2025

SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 12, 2025

All SELLAS Life Sciences Group, Inc. news

Decks

SELLAS Life Sciences Group, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
13 in the last 12 months · 151 in all · newest Sep 25, 2026 · oldest 2019
Calls
1 call with a replay · 1 with a transcript · latest Sep 15, 2022
Decks
19 decks · latest November 2024

Where SELLAS Life Sciences Group, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:SLS · Home listingNASDAQUnited StatesUSD
gettex:RXK3 · This pagegettexGermanyEUR
BOATS:SLSBOATSUnited StatesUSD
Tradegate:RXK3TradegateGermanyEUR
LS Exchange:A2PU3TLS ExchangeGermanyEUR
Lang & Schwarz:A2PU3TLang & SchwarzGermanyEUR
Hamburg:RXK3HamburgGermanyEUR
Dusseldorf:RXK3DusseldorfGermanyEUR
Frankfurt:RXK3FrankfurtGermanyEUR
Munich:RXK3MunichGermanyEUR
Stuttgart:RXK3StuttgartGermanyEUR

Log in to ask 6ix AI your own questions about SELLAS Life Sciences Group, Inc.